Institutional Investors Weigh In On Acumen Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Institutional investors weigh in on acumen pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Institutional Investors Weigh In On Acumen Pharmaceuticals Today - Breaking & Trending Today

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 12.0% in May

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) was the target of a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 816,000 shares, a decrease of 12.0% from the April 30th total of 926,900 shares. Based on an average trading volume of 297,900 shares, […] ....

United States , Dekabank Deutsche Girozentrale , Acumen Pharmaceuticals Trading Down , Institutional Investors Weigh In On Acumen Pharmaceuticals , Sg Americas Securities , Acumen Pharmaceuticals , Chicago Partners Investment Group , Acumen Pharmaceuticals Inc , News Ratings For Acumen Pharmaceuticals Daily , Citigroup Inc , Jump Financial , Acumen Pharmaceuticals Company Profile , Get Free Report , Partners Investment Group , Pharmaceuticals Trading Down , Acumen Pharmaceuticals Daily ,

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 1,050,000 shares, a decrease of 15.3% from the March 31st total of 1,240,000 shares. Based on an average daily volume of 341,300 shares, […] ....

United States , Acumen Pharmaceuticals , Jump Financial , Acumen Pharmaceuticals Company Profile , Acumen Pharmaceuticals Trading , News Ratings For Acumen Pharmaceuticals Daily , Acumen Pharmaceuticals Inc , Franklin Resources Inc , Parkman Healthcare Partners , Chicago Partners Investment Group , Institutional Investors Weigh In On Acumen Pharmaceuticals , Get Free Report , Partners Investment Group , Healthcare Partners , Hudson Bay Capital Management , Bay Capital Management , Acumen Pharmaceuticals Daily , Nasdaq Abos ,

Acumen Pharmaceuticals (NASDAQ:ABOS) Announces Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Acumen Pharmaceuticals (NASDAQ:ABOS) Announces Quarterly Earnings Results, Beats Expectations By $0.07 EPS
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom General , United Kingdom , Credit Suisse Group , Vanguard Group Inc , Acumen Pharmaceuticals Inc , Northern Trust Corp , Securities Exchange Commission , Millennium Management , Acumen Pharmaceuticals Stock , Institutional Investors Weigh In On Acumen Pharmaceuticals , Blackrock Inc , News Ratings For Acumen Pharmaceuticals Daily , Acumen Pharmaceuticals , Earnings History For Acumen Pharmaceuticals , Get Free Report , Marketwatch Earnings , Suisse Group , Director Jeffrey , Exchange Commission , Trust Corp , Hudson Bay Capital Management , Bay Capital Management , Acumen Pharmaceuticals Daily ,

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Director Jeffrey L. Ives Sells 41,949 Shares

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) Director Jeffrey L. Ives sold 41,949 shares of the stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $6.49, for a total value of $272,249.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, […] ....

United States , News Ratings For Acumen Pharmaceuticals Daily , Renaissance Technologies , Credit Suisse Group , Dimensional Fund Advisors , Cantor Fitzgerald , Boothbay Fund Management , Institutional Investors Weigh In On Acumen Pharmaceuticals , Prelude Capital Management , Acumen Pharmaceuticals Trading Down , Acumen Pharmaceuticals , Securities Exchange Commission , Acumen Pharmaceuticals Inc , Get Free Report , Director Jeffrey , Exchange Commission , Pharmaceuticals Trading Down , Suisse Group , Bay Capital Management , Fund Management , Capital Management , Fund Advisors , Acumen Pharmaceuticals Daily , Nasdaq Abos , Insider Trading , Nsider Trades ,

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Growth in Short Interest

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) saw a significant increase in short interest in June. As of June 30th, there was short interest totalling 191,400 shares, an increase of 26.8% from the June 15th total of 151,000 shares. Currently, 0.7% of the company’s stock are short sold. Based on an average daily trading […] ....

Acumen Pharmaceuticals Stock , Acumen Pharmaceuticals Inc , Renaissance Technologies , Credit Suisse Group , Squarepoint Ops , Cantor Fitzgerald , Institutional Investors Weigh In On Acumen Pharmaceuticals , Acumen Pharmaceuticals Company Profile , Acumen Pharmaceuticals , News Ratings For Acumen Pharmaceuticals Daily , Get Free Report , Bay Capital Management , Street Group , Suisse Group , Acumen Pharmaceuticals Daily , Nasdaq Abos ,